Diabetes

Biosimilar QL1207 Demonstrates Equivalent Efficacy and Safety in DME

December 8th 2025

By Skylar Jeremias

Low Prices Fail to Boost Insulin Biosimilar Uptake in the UK

August 11th 2025

By Skylar Jeremias

Biosimilar insulin glargine struggles for market share in the UK, facing pricing challenges and prescriber inertia despite regulatory support and cost-saving potential.

Dulaglutide Biosimilar LY05008 Shows Efficacy and Safety in Treating Type 2 Diabetes

August 7th 2025

By Cameron Santoro

The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and immunogenicity profiles, to the reference drug dulaglutide in Chinese adults with type 2 diabetes.

FDA Approves Kirsty as First Interchangeable Insulin Aspart Biosimilar

July 15th 2025

By Skylar Jeremias

The FDA has approved Kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions.

Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 8th 2025

By Skylar Jeremias

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Strengthening Diabetes Care With Purpose-Built Data Infrastructure

June 18th 2025

By Skylar Jeremias

Explore how real-world evidence and biosimilars enhance insulin access and adherence, improving diabetes care and outcomes for patients who have type 2 diabetes.

How State Substitution Laws Shape Insulin Biosimilar Adoption

April 15th 2025

By Skylar Jeremias

States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.

FDA Approves First Insulin Aspart Biosimilar

February 17th 2025

By Skylar Jeremias

The FDA approved Merilog (insulin-aspart-szjj) as the first biosimilar to reference Novolog (insulin aspart) for the treatment of adult and pediatric patients with type 2 diabetes.

Biosimilars Fuel Price Cuts in European Insulin Glargine Markets

February 14th 2025

By Skylar Jeremias

Although Lantus continues to lead the insulin glargine market globally, the rise of biosimilars like Abasaglar and Semglee has sparked significant price reductions, with some European countries seeing discounts of up to 42.3%.

Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy

November 27th 2024

By Skylar Jeremias

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.